Comparative Pharmacology
Head-to-head clinical analysis: BEOVU versus ZALTRAP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BEOVU versus ZALTRAP.
BEOVU vs ZALTRAP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Brolucizumab is a humanized monoclonal antibody Fab fragment that inhibits vascular endothelial growth factor (VEGF)-A, preventing its binding to VEGFR-1 and VEGFR-2 receptors, thereby reducing endothelial cell proliferation, neovascularization, and vascular permeability.
Vascular endothelial growth factor (VEGF) trap; binds to VEGF-A, VEGF-B, and PlGF, inhibiting angiogenesis.
0.5 mg (0.05 mL of 10 mg/mL solution) by intravitreal injection once every 4 weeks (monthly) for 12 months, then may be extended to once every 8 weeks (every 2 months) based on clinical response.
4 mg/kg intravenously over 1 hour every 2 weeks
None Documented
None Documented
Terminal half-life approximately 26 days (range 23-31 days) in patients with neovascular age-related macular degeneration, supporting monthly intravitreal dosing.
17-18 days (terminal half-life) with clinical context supporting a dosing interval of every 2 weeks; steady-state achieved by approximately 16 weeks.
Primarily metabolic clearance; <1% excreted unchanged in urine. Biliary/fecal excretion not characterized for parent drug.
Primarily via the reticuloendothelial system and proteolytic catabolism; no significant renal or biliary excretion. Renal elimination accounts for <5% as intact drug.
Category C
Category C
VEGF Inhibitor
VEGF Inhibitor